Media & Resources

The International AIDS Vaccine Initiative (IAVI) expresses deep concern over drastic cuts to HIV/AIDS biomedical research and development proposed in the U.S. President’s FY 18 budget. This budget is built on the unfortunate fallacy that the AIDS epidemic can be sustainably controlled using current tools. The proposed 18 percent cut to the President’s Emergency Plan for AIDS Research (PEPFAR) limits capacity…

Canadian Institutes of Health Research funds Gary Kobinger to develop HIV vaccine in partnership with IAVI.

The world lost a leader in the fight against AIDS this week with the passing of Dr. Mark  Wainberg. The pioneering Canadian researcher is widely recognized for his involvement in the 1989 identification of antiviral drug Lamivudine, which is now one of the most extensively used drugs  in  treating  HIV  and its co-infections. “Dr.  Wainberg’s…

The International AIDS Vaccine Initiative (IAVI) announces an expanded partnership with Oxford University to develop a broadly effective AIDS vaccine candidate.

The International AIDS Vaccine Initiative (IAVI) is sponsoring a Phase 1 clinical trial (T001) led by the Beth Israel Deaconess Medical Center (BIDMC) to investigate the safety and tolerability of a broadly neutralizing antibody infusion (bNAb) to prevent HIV infection. A maximum of 93 volunteers will receive one-time infusions of the bNAb PGT121 at varying…

The International AIDS Vaccine Initiative (IAVI) has recently been awarded two new grants by the Bill & Melinda Gates Foundation to expedite the development of promising AIDS vaccine candidates and other new biomedical HIV prevention tools. The grants provide for funding in an amount of almost US$60M over three and a half years. Under these…

New approaches that could spur the human body to produce HIV-blocking antibodies have been successful in mice mimicking the human immune system, according to five studies published today in the research journals Cell, Immunity and Science. The results were produced by scientists affiliated with the International AIDS Vaccine Initiative (IAVI); The Scripps Research Institute (TSRI);…

IAVI to ensure characterization and manufacturing of AIDS vaccine immunogens.